American Electric Power is one of the largest utility holding companies in the United States, but it's lagging behind its peers in renewable energy.
The company reported promising updates for two important pipeline programs.
The filings provide a glimpse of the company's struggles. Can cannabinoids pull the business out of the doldrums?
The year may be drawing to a close, but this biomanufacturing stock -- and any investor interested in it -- has plenty to look forward to.
An important regulatory milestone has been pushed back to late December, although investors will be awaiting voting results from a meeting in mid-November.
The United States and China reached a partial deal in the ongoing trade war.
A new slide deck shows reasons for optimism.
An analyst downgrade is only adding to the company's woes.
An analyst downgrade and a departing executive make for a bad day.
A big contract could keep fueling growth.
The genetic-testing stock can't seem to escape the trap of volatility.
The company more than doubled its cash balance from the end of June with two fundraising transactions.
The path ahead is looking a bit brighter for this pharmaceutical company.
Sometimes stocks go up, sometimes they go down.
The stock continued a slide that began in August, but shares have started heading higher again in October on the heels of promising clinical data.
The growth stock cooled off a bit last month but has still managed to scorch the market with a 51% year-to-date gain.
The threat of a recession hasn't sapped demand for construction projects, which allowed shares to claw their way to a year-to-date high.
Cargo ships could lean on natural-gas-powered fuel cells to significantly reduce carbon emissions. Can the opportunity help Bloom Energy to overcome its struggles?
Most stocks in the industry cooled off from all-time highs. Will they keep sliding?
Two healthcare stocks, two plunging stock prices, and two unique scenarios heading into the end of 2019.